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Aims In 2003, an Australian woman was convicted by a jury of smothering and killing her four children over a 10-year
period. Each child died suddenly and unexpectedly during a sleep period, at ages ranging from 19 days to
18 months. In 2019 we were asked to investigate if a genetic cause could explain the deaths, as part of an inquiry




Whole genomes or exomes of the mother and her four children were sequenced. Functional analysis of a novel
CALM2 variant was performed by measuring Ca2þ-binding affinity, interaction with calcium channels and channel
function. We found two children had a novel calmodulin variant (CALM2 G114R) that was inherited maternally.
Three genes (CALM1-3) encode identical calmodulin proteins. A variant in the corresponding residue of CALM3
(G114W) was recently reported in a child who died suddenly at age 4 and a sibling who suffered a cardiac arrest
at age 5. We show that CALM2 G114R impairs calmodulin’s ability to bind calcium and regulate two pivotal calcium
channels (CaV1.2 and RyR2) involved in cardiac excitation contraction coupling. The deleterious effects of G114R
are similar to those produced by G114W and N98S, which are considered arrhythmogenic and cause sudden car-
diac death in children.
...................................................................................................................................................................................................
Conclusion A novel functional calmodulin variant (G114R) predicted to cause idiopathic ventricular fibrillation, catecholaminer-
gic polymorphic ventricular tachycardia, or mild long QT syndrome was present in two children. A fatal arrhythmic
event may have been triggered by their intercurrent infections. Thus, calmodulinopathy emerges as a reasonable
explanation for a natural cause of their deaths.
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Introduction
Few diagnostic odysseys involve such high stakes as the quest to de-
termine whether recurring sudden unexpected deaths (SUD) of chil-
dren in a single family are the result of natural causes or infanticide. In
the late 1990s and early 2000s, a series of high profile convictions of
British mothers involved the statistical testimony of eminent paedia-
trician, Sir Roy Meadow, in support of his general rule that ’one sud-
den infant death is a tragedy, two is suspicious and three is murder,
until proved otherwise’.1 While the maxim has since been discredited
and several mothers, including Sally Clark and Angela Cannings have
had their convictions overturned,2,3 an Australian woman has
remained imprisoned.
In 2001, a mother from Newcastle in New South Wales was
arrested and charged with smothering and killing her four young chil-
dren. Each child died suddenly during periods of rest over the course
of 10 years (1989–99) (Supplementary material online, p. 16, Table
S1) Child 1 (male) died at 19 days having been diagnosed with ‘laryng-
omalacia’. Child 2 (male) died at 8 months from asphyxia due to air-
way obstruction in turn due to epileptic fits from an
encephalopathic disorder of unknown cause associated with
blindness. Child 3 (female) died at 10 months old, four days after
seeing her GP for a croupy cough and being started on antibiotics
(flucloxacillin); autopsy findings included a congested and hae-
morrhagic uvula and profuse a-haemolytic Streptococcus in lung
cultures. Child 4 (female) died at 18 months old, two days after
being treated with paracetamol and pseudoephedrine for a respi-
ratory infection. At autopsy she was found to have florid myocar-
ditis (Figure 1) and spleen cultures grew profuse a-haemolytic
Streptococcus of two colonial types and moderate Staphylococcus
aureus (Supplementary material online, p. 16, Table S1).4
Circumstantial evidence against the mother consisted primarily of
tendency and coincidence evidence echoing Meadow’s Law, and
seemingly inculpatory diary entries.5 This evidence was thought to
outweigh that in favour of death by natural causes.5 In 2003, a jury
found the mother guilty of the manslaughter of Child 1 and the mur-
ders of the remaining 3 children, notwithstanding that there was no
history of abuse, no physical signs of smothering, no obvious motive,
no eye witnesses, and no admission of guilt.5 Psychiatrists that
assessed the mother in the early 2000s considered her not to be suf-
fering from any psychiatric illness that could explain infanticide, such
as personality disorder, psychopathy, psychosis, schizophrenia, bipo-
lar disorder, or Munchausen’s syndrome by proxy. A psychiatrist that
provided evidence to the inquiry and assessed the mother in March
2019 agreed that she did not suffer from a psychiatric illness that
could explain infanticide but considered her to be suffering from
complex post-traumatic stress disorder dating to her childhood.6,7
To date the mother has maintained her innocence.
Graphical Abstract
What’s new
• This study identifies a novel and functional calmodulin variant
(CALM2 G114R) present in a mother convicted of infanticide
and her two female children.
• Biochemical and electrophysiological studies of the G114R vari-
ant show that it has deleterious effects on calcium binding and
regulation of the two pivotal calcium channels involved in cardiac
excitation contraction coupling, CaV1.2 and RyR2, in a similar
manner to that of the pathogenic G114W and N98S variants.
• Given the biophysical and functional impact of the CALM2
G114R variant, we consider the variant likely precipitated the
natural deaths of the two female children (Child 3 and 4).
• The two male children (Child 1 and 2) carried biallelic rare
missense variants in BSN, a gene shown to cause early onset le-
thal epilepsy in mice when deleted.
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In March 2019, a judicial inquiry into the mother’s convictions
commenced due to concerns raised by several forensic pathologists
regarding the medical evidence provided at the trial. The results pre-
sented here follow on from genomic investigations conducted at the
request of the inquiry. The inquiry concluded before we completed
our functional analysis and the mother remains in prison. All the clini-
cal, pathology, and legal case information, including the mother’s
prison health records, and the children’s medical and autopsy records
are publicly available in the exhibits to the inquiry and can be
accessed via: https://www.folbigginquiry.justice.nsw.gov.au/Pages/
documents.aspx.
The hypothesis that a genetic variant causing respiratory failure
or arrhythmia could explain the SUD of the children provided the
rationale for genomic studies. The four children suffered from
conditions of varying clinical significance (Supplementary material
online, p. 16, Table S1). Child 1 (male) had difficulty breathing from
birth attributed to laryngomalacia, Child 2 (male) suffered epileptic
seizures from age 4.5 months until his death, Child 3 (female) likely
had a respiratory infection at the time of her death, and Child 4 (fe-
male) had myocarditis visible on autopsy (Figure 1). The children’s
various conditions suggested that if there was a single underlying
natural cause it was likely to have a spectrum of clinical manifesta-
tions and lethal triggers. Inherited arrhythmogenic disorders capa-
ble of causing sudden cardiac death (SCD) fit this profile and may
first manifest as SUD.8
Unfortunately, the cardiological assessments of the children
were limited. There were no ECG recordings of Child 1. ECG
recordings of Child 2 from the early neonatal period and at
4 months of age showed normal sinus rhythm and normal inter-
vals including a QTc of 380 ms. There were no ECG recordings of
Child 3. ECG recordings of Child 4 at age 11 days showed normal
sinus rhythm and normal intervals including QTc of 380 ms. Aside
Figure 1 H&E staining of cardiac sections from Laura’s autopsy. Inflammatory infiltrates are seen in the myocardium associated in places with myo-
cyte necrosis (magnification: 100–400).
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from Child 4’s myocarditis, examination of each childs’ heart did
not reveal cardiac abnormalities.
Calmodulinopathies are rare life-threatening arrhythmia syn-
dromes caused by pathogenic variants in one of the three genes
(CALM1, CALM2, and CALM3) that encode identical calmodulin pro-
teins.9 Calmodulin (CaM) is a calcium-binding protein that regulates
an array of enzymes and ion channels in a calcium-dependent
manner, including those essential for regulating cardiac contractil-
ity. Specifically, CaM is key to the calcium-dependent inactivation
(CDI) of cell membrane calcium channel CaV1.2, and for timely
closure of the cardiac sarcoplasmic reticulum (SR) calcium release
channel, RyR2. The first human CaM missense mutation was iden-
tified in 2012 in a large Swedish family segregating with catechol-
aminergic polymorphic ventricular tachycardia (CPVT) and
multiple cases of SCD.10 The first CaM mutations associated with
long QT syndrome (LQTS) and cardiac arrest in infants were
identified in 2013.11 The International Calmodulinopathy Registry
(ICalmR) (n = 74; 35 different pathogenic genotypes) reveals vari-
ability in clinical manifestations. Long QT syndrome (49%) and
CPVT (28%) present at a median age of 1 year and 6 months and 6
years, respectively. Other presentations include idiopathic ven-
tricular fibrillation (IVF), SUD, overlapping features of CPVT/
LQTS and predominant neurological phenotype, while 13.5% are
asymptomatic.9
Methods
Human subjects and DNA sequencing
The mother provided informed written consent to conduct genomic re-
search and testing of herself and her children. The mother’s genomic
study complies with ethical regulations of the Australian National
University and Australian Capital Territory Health Human Ethics
Committees. Whole genome sequencing (WGS) of Child 1 and whole
exome sequencing (WES) of Child 4 was performed from neonatal
screening cards and WGS of the mother, Child 2, and Child 3 from buccal
swab, frozen liver tissue, and a fibroblast cell line respectively. The aver-
age coding exon coverage was 77 for the mother, 45 for Child 1, 59
for Child 2, 47 for Child 3, and 172 for Child 4. The coverage was cal-
culated after removal of ambiguously mapped and orphaned reads.
Bioinformatics analysis is described in Supplementary material online, pp
4-5. The mother agrees to share the genetic and clinical data of her chil-
dren upon request for research purposes. Upon request, L.C. and P.J.S.
will share the ICalmR data not publically available.
Calmodulin protein production and
purification
Calmodulin variants were expressed in an Escherichia coli Rosetta (DE3)
strain from a modified pET vector with an N-terminal maltose-binding
protein and tobacco etch virus cleavage site. Calmodulin purification is
described in Supplementary material online, p. 5.
Secondary structure determination by
circular dichroism
Circular dichroism spectra were recorded at 37C using a Chirascan-Plus
circular dichroism spectrometer as described previously and summarized
in Supplementary material, p. 5.12
Calcium binding
Calcium titration experiments were performed as described previously
and summarized in Supplementary material, p. 5.13,14
Calmodulin binding to the CaV1.2 IQ-
domain and RyR2 CaMBD2
Peptides representing the CaV1.2 IQ-domain and RyR2 CaM-binding do-
main 2 (CaMBD2) (Supplementary material, pp. 5–6) with an N-terminal
5-carboxytetramethylrhodamine (5-TAMRA) label were obtained from
Proteogenix (>95% purity). Calmodulin binding to the IQ-domain and
CaMBD2 peptides was monitored by fluorescence anisotropy of the 5-
TAMRA-labelled peptide (Supplementary material, p. 6). Binding was
measured at a range of Ca2þ concentrations in the presence of 1 mM
free Mg2þ, controlled by the Ca2þ/Mg2þ-buffer system described previ-
ously and in Supplementary material, p. 5.
Cellular electrophysiology of CaV1.2
CaM mutations were generated on the human CALM1 gene in the
pIRES2-EGFP vector (Clontech Laboratories, Inc.).15 For whole-cell
patch clamp experiments, HEK293 cells (ATCC) were transiently trans-
fected with human cardiac a1C cDNA,
16 rat brain b2a (M80545), rat brain
a2d (NM012919.2) subunits, CaM variants, and simian virus 40T antigen
using a standard calcium phosphate method. The details of voltage-clamp
recordings, solutions, and quantification of currents can be found in
Supplementary material, p. 6.
Store overload induced calcium release
assay
Calcium levels in the endoplasmic reticulum of HEK293 cells expressing
RyR2 and CaM variants were monitored using single-cell Ca2þ imaging
and the Ca2þ-sensitive fluorescence resonance energy transfer-based
cameleon protein D1ER, as previously described and detailed in
Supplementary material, p. 6.17
Results
The mother reported recurrent episodes consistent with transient
loss of consciousness that started in childhood. These episodes have
been associated with intercurrent illnesses, physical exertion includ-
ing swimming and running, emotional stress, and pregnancy
(Supplementary material, p. 16, Table S1). Her ECGs, cardiac exercise
stress test, and 24 h Holter were normal.
We performed WGS of the mother and the first three children
and WES of the fourth child. The children’s father declined
requests to provide a DNA sample, and was not ordered to pro-
vide one by the Inquiry. Twenty-nine ultrarare [minor allele fre-
quency (MAF) < 0.0005] variants occurred in 4/4 children
(Supplementary material, p. 17, Table S2) in genes not known to
cause SUD. Next, we searched specifically for ultrarare variants in
424 genes extracted from a literature review of causes of SUD,
SCD, SIDS, cardiac or arrhythmogenic conditions, and epileptic
encephalopathy (Supplementary material, p. 18, Table S3) and
identified variants in 12 genes: CACNA1E, CACNA1G, CALM2,
CTNNA3, DMD, DMPK, DOCK7, JUP, KCNAB2, MYH6, MYLK,
SCNN1A, and BSN (Supplementary material, p. 19, Table S4). In ad-
dition, analysis of immune variants identified two missense
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variants associated in the literature with susceptibility to bacterial
lung infections (PTPN13, 4/4 children)18 or myocarditis (NLRP1,
novel, 3/4 children)19 (Supplementary material, p. 19, Table S5).
Child 2’s genome was found to carry a novel IDS variant located in
the same codon as a known Hunter’s Sd mutation
(Supplementary material, p. 19, Table S6).
Of the 12 cardiac/SCD/SUD/epilepsy variants, only CALM2 and
KCNAB2 caused human genetic disorders associated with SUD
according to the OMIM catalogue. KCNAB2 (p.Ala11Thr, A11T;
c31G>A, MAF = 0.000004) was present in 3/4 children. Although we
have shown previously that gain-of-function missense mutations in
adjacent residues (R12Q and L13F) are associated with Brugada
syndrome,20 functional analysis of KCNAB2 A11T was normal
(Supplementary material, pp. 3, 9, 20, Figure S2, and Table S7). The
two male children (Child 1 and Child 2) had biallelic rare missense
variants in BSN (Bassoon): p. L1898M (MAF = 0.000008) and p.
A355T (MAF = 0.0022), both predicted to be damaging
(Supplementary material, p. 19, Table S4). BSN is important for
presynaptic function and for formation and function of photore-
ceptor ribbon synapses of the mammalian retina.21 In mice, BSN
deficiency causes early onset severe epilepsy that is 50% lethal in
the first 6 months of life.22 To date, heterozygous BSN variants
have been associated with an adult-onset progressive-supranu-
clear palsy-like syndrome23 but an autosomal recessive form of
this disease has not yet been described.
The CALM2 variant (p.Gly114Arg, G114R; c.340G>A) was present
in the mother and the two female children (Child 3 and Child 4)
(Figure 2A and C and Supplementary material, pp. 8, 19, Figure S1, and
Table S4). DNA from the mother’s parents was not available. Neither
Sanger sequencing nor WGS/WES of the mother’s saliva and buccal
swab samples was suggestive of mosaicism for CALM2 G114R [saliva:
76 reference (C): 84 variant (T) reads; Buccal swab: 106 reference
(C): 104 variant (T) reads] and a blood sample could not be obtained.
Sanger sequencing could not be performed on Child 3 and Child 4
due to lack of access to additional DNA. The CALM2 G114R variant
is not found in databases of human genetic variation (ExAC,
gnomAD, 1000 genomes, ClinVar). We have not observed the vari-
ant in 2580 in-house genomes sequenced at the Australian National
University or in genomes from 2485 elderly Australians (MGRB).24
Overall, CALM2 is highly intolerant to missense substitution.25 G114R
is predicted as damaging by multiple in silico tools; and the phenotype
is specific for disease (SUD in infancy and childhood).26 Indeed, five
different CaM mutations causing sudden death or cardiac arrest in
children while asleep have been reported (three of them in children
<2 years old), all of which are physically close to the G114 residue in
the three-dimensional structure of CaM (Figure 3A).
Residue G114 in CaM is highly conserved and located in the linker
domain between EF-hand III-IV (Figure 3A). The CALM2 G114R vari-
ant results in a unique amino acid substitution, but a different substi-
tution in the corresponding codon of CALM3 (G114W) is known to
1 2
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Figure 2 Pedigrees of kindreds with G114R and G114W CALM mutations and Sanger sequencing. (A) Folbigg family pedigree (kindred A) showing
inheritance of CALM2 gene and the protein variation glycine (G) at position 114 to arginine (R). (B) Pedigree showing inheritance of CALM3 gene and
protein variant G114W (tryptophan; W) in kindred B. Shaded circles represent affected individuals with SUD/SCD/CA. (C) Sanger sequencing from
KF’s buccal swab highlighting the C!T variant. WT, wild type.
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be pathogenic(Figure 2B);9 CALM3 G114W was identified in two sib-
lings, a girl who died suddenly at age 5 and a brother who suffered a
cardiac arrest at age 4 (Figure 2B).9 Their mother was healthy and
found to be a mosaic, with no apparent cardiac phenotype.
Ca2þ-sensing and Ca2þ-channel regulation by CaM is crucial for
maintaining a stable and healthy heart rhythm (Supplementary
material, pp. 3–4). Further investigations revealed that CaM-G114R
decreased the Ca2þ-binding affinity of the C-domain of CaM, with
a similar magnitude of effect to that observed with known
arrhythmia-causing mutations, G114W and N98S (Figure 3B and
Supplementary material, p. 20, Table S8). CaM-N98S was included for
comparison, as this is one of the best characterized CaM mutations
and it has been found in 10 unrelated individuals (5 in CALM1 and 5 in
CALM2), causing either SUD (including in a 2-year-old while asleep),
A
B
Figure 3 G114R and G114W mutations impair the calcium binding strength of CaM. (A) Three-dimensional structure of CaM (PDB: 1cll). Ca2þ-
ions are displayed as black spheres. Mutations at green residues have been associated with SUD/CA during sleep in other patients. (B) Ca2þ-binding
curves (left) of the C-terminal domain of CaM variants N98S, G114R, and G114W, showing reduced Ca2þ affinity (right), a likely proarrhythmic sub-
strate. Data displayed as mean ± SD. *P <_ 0.05, **P <_ 0.01, and ***P <_ 0.001 using one-way ANOVA with Dunnett’s post hoc test against CaM-WT.
CA, cardiac arrest; CaM, calmodulin; FInorm, normalized fluorescence intensity; IVF, idiopathic ventricular fibrillation; KA, association constant; LQTS,
long QT syndrome; SCD, sudden cardiac death; SUD, sudden unexplained death.
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IVF, LQTS, CPVT, or a mixed LQTS/CPVT phenotype. We postu-
lated that the reduced Ca2þ-binding affinity results from a structural
change conferred by the G114R mutation and observed that in the
presence and absence of Ca2þ, CaM-G114R contains more alpha-
helices and fewer turns and disordered regions (Supplementary ma-
terial, pp. 10–11, Figures S3 and S4). The structural effect of CaM-
G114R was comparable to that of the arrhythmogenic G114W mu-
tation. Thus, both mutations increase the structural stability of the
CaM C-domain.
We next investigated the effect of CaM-G114R on calcium flux by
investigating CaM binding to the IQ-domain and CaM-binding domain
2 (CaMBD2) of the CaV1.2 and RyR2 cardiac Ca
2þ-channels, respec-
tively. We found that the G114R mutation reduces the affinity of
CaM for both the IQ-domain (Figure 4A–C) and CaMBD2
(Figure 4E–G) at low and medium Ca2þ-concentrations at least as
much as the known arrhythmogenic N98S and G114W variants. At
high Ca2þ-concentrations, there was no significant difference be-
tween the CaM variants (Figure 4D and H). Thus, the G114R variant
mutes the Ca2þ-sensing action of CaM when complexed with the
canonical binding domains from CaV1.2 and RyR2 with an effect simi-
lar to or larger than known pathogenic variants, G114W and N98S
(Supplementary material, pp. 12–13, Figures S5 and S6).
We also investigated the action of CaM-G114R on intact CaV1.2
and RyR2 channel function. Calmodulin controls the CDI of CaV1.2
(Supplementary material, pp. 3–4, 14, Figure S7). We observed that
CaM-G114R decreased CDI of CaV1.2 to the same extent as CaM-
G114W but less than CaM-N98S (Figure 5A, B and Supplementary
material, pp. 3–4, 14, Figure S7), which has been linked to a mixed
CPVT/LQTS phenotype. In contrast, the most damaging CaM var-
iants that cause severe LQTS, such as D96V, F142L, or D130G, fully
abolish CDI.15 Finally, we also investigated the action of CaM on
RyR2 closure in a negative-feedback mechanism (Supplementary ma-
terial, pp. 4, 15, Figure S8).17 Normally, CaM exerts its CDI effect on
RyR2 by increasing the SR luminal Ca2þ-termination threshold for
store-overload induced Ca2þ release (SOICR). We observed that
CaM-G114R decreased the termination threshold for SOICR, equiv-
alent to the effect observed for CaM-G114W and CaM-N98S14
(Figure 5D). Curiously, CaM-G114W, but not CaM-G114R, also sig-
nificantly reduced the SOICR activation threshold compared to
CaM-WT (Figure 5C). All three mutations resulted in a significant in-
crease in fractional Ca2þ release during SOICR14 (Figure 5E). In sum-
mary, these functional studies reveal that CaM-G114R fails to close
the CaV1.2 and RyR2 channels normally, which leads to excess trans-
port of Ca2þ through both channels. This dysregulation mechanism is
common to arrhythmogenic CaM variants.27
Discussion
Our main findings are that the mother and her two female children
(Child 3 and Child 4), were carriers of a novel and functional variant
in the CALM2 gene associated with sudden death in infancy and
A B C D
E F G H
Figure 4 G114R and G114W mutations impair the binding of CaM to calcium channels. (A–D) Ca2þ-dependent binding of CaM to the IQ-domain
of CaV1.2. Reduced binding of CaM variants N98S, G114R, and G114W unbalances the fine regulation of CaV1.2 by CaM at low and intermediate
Ca2þ concentrations, predisposing to an altered Ca2þ inflow through CaV1.2. (E–H) Similarly, the binding to the RyR2 CaMBD2 domain was de-
creased at low and intermediate Ca2þ concentrations, suggesting an altered Ca2þ outflow from the sarcoplasmic reticulum. *P<_0.05, **P<_0.01, and
***P<_0.001 using one-way ANOVA with Dunnett’s post hoc test against CaM-WT values. CaM, calmodulin.









niversity user on 08 D
ecem
ber 2020
childhood, and that the variant is predicted to be arrhythmogenic.
The variant found in the female children (G114R) affects the same
amino acid as a variant in an identical protein encoded by CALM3
(G114W), which was implicated in the SCD of one child and the car-
diac arrest of another. Both G114R and G114W variants conferred
similar structural changes in CaM. Both variants compromise the abil-
ity of CaM to sense changes in Ca2þ concentration, and impair bind-
ing to, and regulation of, the two cardiac Ca2þ-channels CaV1.2 and
RyR2. These effects are also similar to those observed with CaM-
N98S, which has been found in 10 unrelated patients diagnosed with
either LQTS, CPVT, a mixed phenotype, IVF, or suffering from SUD.9
It is noteworthy that one N98S carrier experienced SUD while
asleep at 2 years of age.9 Sudden death during sleep is not an excep-
tional presentation of calmodulinopathies: of the 74 patients
reported in the ICalmR, 20 suffered SUD/SCD and 5 of these (25%)
died suddenly or suffered cardiac arrests in their sleep. Of those five,
three occurred in children below age 2.9
Mechanistically and functionally, calmodulinopathies follow a sur-
prisingly consistent scheme.9 For almost all described cases, CALM
mutations specifically affect the heart and cause arrhythmia, fibrilla-
tion, and/or cardiac arrest.28 In vitro assessment of CALM mutations,
has revealed an elegant correlation between the clinical manifestation
A B
C D E
Figure 5 G114R and G114W mutations cause delayed closure of calcium channels CaV1.2 and RyR2. (A) Exemplar traces of electrophysiological
recordings of CaV1.2 opening (downward deflection) and subsequent CaM-mediated calcium-dependent inactivation (CDI) (return towards baseline)
during a 30 mV voltage clamp in the presence of Ca2þ (red) or Ba2þ (black). (B) CDI as quantified by the metric f300, measured at 30 mV. All three
CaM mutations significantly reduce CDI, thus increasing the Ca2þ inflow through CaV1.2 and potentially leading to a pathogenic QT prolongation.
***P < 0.001 using Student’s t-test. Quantified RyR2 channel opening (C) and closure (D) propensity as well as the amount of Ca2þ released (E) during
an open event in store-overload induced calcium release (SOICR) assay. The CaM variant G114W significantly reduced the activation threshold, and
the variants G114R and G114W significantly altered the termination threshold and fractional calcium release, potentially leading to an arrhythmogenic
enhanced intracellular Ca2þ level. Data are displayed as mean ± SEM. *P <_ 0.05 and **P <_ 0.01 using one-way ANOVA with post hoc test. CaM, cal-
modulin; CaV1.2, voltage-gated calcium channel isoform 1.2; RyR2, ryanodine receptor type 2; WT, wild type.









niversity user on 08 D
ecem
ber 2020
and their impact on (i) Ca2þ sensing and structure of the CaM pro-
tein and (ii) how CaM regulates the two Ca2þ-channels CaV1.2 and
RyR2.27 In most cases, the clinical impact is directly reflected in the
regulation of these two Ca2þ-channel targets. Calmodulin mutations
that severely reduce Ca2þ-binding to the C-domain and completely
abolish CDI are present in patients with severe early onset
LQTS.15CPVT-associated CaM mutations consistently exert a
smaller impact on Ca2þ-binding, and minimal or no effect on CaV1.2
regulation, and have little or no effect on the QT interval.13,15
Dysregulation of RyR2 Ca2þ-release is generally considered the un-
derlying cause of CPVT, and this is also the effect observed for all
CPVT-associated CaM mutations.14,29
Based on the previous studies and the functional data presented
here, we predict that the G114R and G114W variants are pathogenic
and that carriers are therefore prone to cardiac arrhythmias of IVF or
CPVT-like phenotypes with a potential component of mild LQTS,
which could cause cardiac arrest during sleep. This prediction is
based on the following observations: (i) Both mutations impair RyR2
binding and regulation to a similar extent as other known CPVT-
associated CaM mutations29; (ii) Both mutations impair CaV1.2 CDI
to an intermediary extent, consistent with a possible mild LQTS, but
likely not severe LQTS15; (iii) The mutations are not among the most
severe in terms of reduced Ca2þ sensing, likely due to the location in
a linker region between Ca2þ-binding sites; (iv) The effect of the
mutations are experimentally similar to N98S, which has been associ-
ated with LQTS, CPVT, IVF, or a mixed phenotype; and (v) SUD at a
young age has been observed for a number of other calmodulinop-
athy cases,9 including a carrier of an N98S mutation (SUD while
asleep) which displays a similar functional impact as the G114R and
G114W mutations. Of note, the girl with the G114W mutation who
suffered a CA was diagnosed with IVF.
In this family, the CALM2 variant was inherited from their extant
mother, who did not appear to be a mosaic. Incomplete penetrance
or variable expressivity occur frequently in heritable cardiac arrhyth-
mia syndromes,8,30 including calmodulinopathies.31 There are multi-
ple reports of the same CaM mutation giving rise to different clinical
manifestations/phenotypes in different individuals, including families,
in which the parental carrier has relatively mild symptoms, such as
frequent syncope as was the case with the mother, while the children
suffer from life-threatening arrhythmias.9,10,31,32 Familial cases of
CALM-CPVT and CALM-IVF with asymptomatic carriers have been
previously reported.9,32 For example, Marsman et al.32 reported a
family with a CALM1 variant (F90L) that caused IVF in childhood and
adolescence. Five children inherited the variant from their mother.
Four children suffered cardiac arrests or sudden death, but the fifth
child (age 14 years) and the mother (age 60 years) remain asymptom-
atic after 7 years of follow-up. The ICalmR reports that 13.5% of
patients with pathogenic CALM variants have experienced no cardiac
events.31
Phenotypic variation is often the consequence of modifier genes.33
These are genetic variants capable of either increasing or decreasing
the clinical severity produced by a disease-causing mutation. Recently
a mechanism of action of a protective modifier gene has been de-
scribed for LQTS: the family members carrying this protective vari-
ant, which compensates the loss of potassium current produced by
the disease-causing mutation, had a completely normal ECG and QT
interval.34
Phenotypic variation also raises the possibility of environmental,
iatrogenic, or infectious triggers. Fever has been shown to be a trigger
of cardiac arrhythmias and SCD/SUD in childhood.35 Both Child 3
and Child 4 suffered from respiratory infections immediately prior to
their deaths. At present, no research has addressed the influence of
infection or fever on the arrhythmogenic risk of calmodulinopathy
patients. . Serious infections might have caused an elevated catechol-
amine state, 36,37,38 which has been associated with trigger activity
due to delayed after-depolarizations under conditions of calcium dys-
regulation.38 Furthermore, Child 4 was treated with pseudoephed-
rine, a sympathomimetic that activates a- and b-adrenergic receptors
and causes release of endogenous catecholamines, which are the trig-
gers of CPVT. She also suffered from myocarditis, which is thought to
be a major cause of SCD in the first two decades of life.39
Combinations of these factors may have triggered the lethal events.39
Child 1 and Child 2 were compound heterozygotes for rare mis-
sense variants in BSN (Bassoon) whose deficiency is known to cause
early onset lethal epilepsy in mice.22 BSN is a gene that appears to be
highly intolerant to loss-of-function (pLI = 1). These variants require
further investigation to determine whether they might account for
Child 2’s severe epilepsy and blindness.21
Conclusions
The data presented here indicate that molecular autopsies including
WES/WGS are warranted for SUD infanticide cases where the ac-
cused was convicted on purely circumstantial evidence. The growing
understanding of inherited cardiac arrhythmias8 forces a reassess-
ment of the medical foundations, never challenged, on which several
mothers were found guilty of infanticide on the basis of assumption
instead of evidence. The genomic revolution heralds a new era for
the assessment of recurring familial sudden deaths of infants and chil-
dren, an era that reasserts the presumption of innocence for tragi-
cally unlucky families.
Supplementary material
Supplementary material is available at Europace online.
Acknowledgements
We are grateful to Luca Sala for constructive criticism and Stephen
Cordner for providing the cardiac photomicrographs. We acknowl-
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